Uutiset & PR

 

Alta löydät yritystämme koskevia uutisia ja ladattavia logoja ja kuvia.

Mikäli sinulla on kysyttävää tai muuta lehdistöön & mediaan liittyvää asiaa, otathan yhteyttä osoitteeseen cerff@bevsnez.pbz  

Uutiset

24.04.2020

Orifarm Group on allekirjoittanut sopimuksen suuresta, miljoonien eurojen ostosta Takedalta

Orifarm Group (”Orifarm”), yksi Pohjoismaiden johtavista lääkealan yhtiöistä, on solminut sopimuksen, jolla se ostaa Takeda Pharmaceutical Company Limitediltä (”Takeda”) valikoidun tuotevalikoiman Euroopassa myytäviä itsehoito- ja reseptilääkevalmisteita. Ostohinta on jopa 615 miljoonaa euroa. Orifarm on hankkinut oikeudet noin 110 lääkkeeseen sekä kaksi tuotantolaitosta.

Lehdistötiedote

Orifarm Group (”Orifarm”), yksi Pohjoismaiden johtavista lääkealan yhtiöistä, on solminut sopimuksen, jolla se ostaa Takeda Pharmaceutical Company Limitediltä (”Takeda”) valikoidun tuotevalikoiman Euroopassa myytäviä itsehoito- ja reseptilääkevalmisteita. Ostohinta on jopa 615 miljoonaa euroa. Orifarm on hankkinut oikeudet noin 110 lääkkeeseen sekä kaksi tuotantolaitosta.

Lehdistötiedote

20.03.2020

Orifarm Group A/S with new record-breaking result

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.

Read the press release here

 

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.

In 2019, the turnover of the Orifarm Group reached MEUR 982. An 18% increase compared to the record-breaking year 2018. Profit before tax in 2019 reached MEUR 45.4 corresponding to a rise of 30% compared to the previous record from the financial year 2018.

The progress in 2019 is mainly attributable to a strong sales growth of parallel imported pharmaceuticals at the German market, which is also Orifarm’s largest market. Orifarm increased its market share and generated both higher turnover and earnings. Also generic pharmaceuticals showed progress where in particular the Norwegian market grew.

For Orifarm’s CEO Erik Sandberg the result is more than approved.

- We have all worked hard and been careful not to rest on the laurels from last year’s result, and I am proud of the result we have achieved as a team. In addition to the awesome result we have also implemented a number of digitalization projects in our operation, which will make us even more competitive in the future. A future, of which we have high hopes. 

Targets of continued growth

Orifarm Group has ambitions to continue the growth in the next few years. There is still a lot of potential within the two existing business areas, parallel imported pharmaceuticals and sale of generic pharmaceuticals. All in all, Orifarm has sold more than 26 million boxes of medicine in 2019. This entails another record for Orifarm.

In 2019, operating income increased by MEUR 7.8 to MEUR 48.1.

The parallel import business has not only increased the turnover in Germany, but also in Finland, Austria, and United Kingdom. However, the exchange rates in especially United Kingdom and Sweden have affected the earnings unfavorable.

The sale of generic pharmaceuticals in the Nordic countries has also been in clear progress in 2019, where turnover has increased with nearly 8%. 

Acquisition – a part of the growth strategy

Contemporary with the growth of the present business, Orifarm Group acquired the London based company Pilatus Comparator Solutions during summer 2019. Pilatus adds new business areas like comparator sourcing and unlicensed medicines to Orifarm Group.

- The acquisition of Pilatus is an example of the fact, that we keep a close eye on possible acquisitions which have synergies in terms of our present business areas. Pilatus has added some new activities, which we are about to develop and which we can infuse with a lot of muscle work with our comprehensive experience in parallel import, says Orifarm’s CEO Erik Sandberg. 

Outlook for 2020

Orifarm Group’s target is a minor growth in revenue in 2020 and retention of earnings at 2019 level. 

For further information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351
CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121 

Key ratio – Orifarm Group (in MEUR)

 

2019

2018

  2017

2016

Revenue

982

833

797

726

Gross profit

150

131

120

109

Operating income excl. non-recurring items

48

40

34

32

Net financials

-2

-3

-5

-8

Profit before tax

45

35

29

16



Facts about Orifarm Group
Orifarm Group is the largest supplier of parallel imported pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group is engaged in parallel import of medicines from the EU/EEA which are sold to Denmark, Norway, Sweden, Finland, Germany, The Netherlands, Austria, United Kingdom, and Belgium.

In addition to this, the Group is engaged in the sale of generic pharmaceuticals in the Nordic countries. A generic pharmaceuticals contain the same effects as the original pharmaceutical. However, the effect is no longer subject to patent and therefore the generic pharmaceutical can be produced and marketed at a lower price than the corresponding original pharmaceutical.

Orifarm Group has its headquarters in Odense and the entire Group employs close to 1,200 people today, of which around 360 in Odense.

29.05.2019

Orifarm presents best result ever

For Orifarm, 2018 was a fantastic year. In fact, the best in the company's nearly 25-year history. Every day, the employees work hard to challenge the pharmaceutical market to provide cheaper pharmaceuticals to millions of consumers in Europe. And the employees do it well. In 2018, Orifarm Group sold more than 25 million products - or approx. 7% more products than in 2017, and this has resulted in record turnover and earnings.

 

For Orifarm, 2018 was a fantastic year. In fact, the best in the company's nearly 25-year history. Every day, the employees work hard to challenge the pharmaceutical market to provide cheaper pharmaceuticals to millions of consumers in Europe. And the employees do it well. In 2018, Orifarm Group sold more than 25 million products - or approx. 7% more products than in 2017, and this has resulted in record turnover and earnings.

This week, Orifarm Group releases its 2018 Annual Report and the result beats all former company records. The Group's revenue increased by 4.7 % in 2018 to MEUR 833. Operating income excl. non-recurring items increased by MEUR 6.5 to MEUR 40.3, and earnings before tax increased to  record high MEUR 34.9. A very satisfactory result for the Group, which also exceeds the expectations.

Erik Sandberg, who officially took over as CEO in January 2019, says:

“In many ways, 2018 has been a fantastic year for us. A year where we have met lots of challenges in the markets, and where we have been through a major reorganization internally. Nevertheless, we have succeeded in creating great results for the Group together. It proves our willingness and ability to make a difference - for consumers, society and the company. All employees can be proud of what we achieved together in 2018, as it would not have happened without them.”

More consumers have bought Orifarm's products

The Group's financial growth was especially generated in the parallel import business, which repackages and sells pharmaceutical products within the EU / EEA. The parallel import business sold 11 % more products in 2018 compared to 2017, which led to growth in both revenue and earnings in 2018.

The 2018 revenue from parallel imported products totalled MEUR 756. This is an increase of 4.9 % compared to 2017. The result of main activities excl. non-recurring items increased by MEUR 8.0 to MEUR 34.2.

In spite of intense competition in 2018, Orifarm succeeded in generating great results in Germany, which is the Group's largest market, as well as in Denmark, the Netherlands and Austria.

In Sweden, the Group's earnings has been under pressure due to the Swedish currency exchange rate, but Orifarm maintained its position at the Swedish market. The parallel import business sold more products in the UK in 2018 compared to the previous year, but the weak British currency puts pressure on the profit.

The Group's other business area, the generic pharmaceuticals, had a difficult year with stagnation in revenue and decreasing income. Nevertheless, the generic pharmaceuticals sold 4 % more products in 2018 compared to the year before.

Challenging market conditions and challenges in maintaining a stable supply of few, and normally well performing products, put pressure on the Group's revenue and earnings from the generic products.

Operating income fell by MEUR 2.6 to MEUR 9.7, however, it was possible to maintain revenue at the same level as in 2017 (MEUR 9.7).

“We have done well in 2018 in difficult conditions, and we have the ambition and the belief in being able to continue growth and a positive development for Orifarm. But we are also realistic and 2019 will be at least as challenging as 2018, characterized by strong competition at all Orifarm's markets. But we have so many skilled employees who drive Orifarm forward. Therefore, I am confident that together we can meet the common goals for 2019,” says Erik Sandberg, CEO at Orifarm Group.

Expectations for 2019

For 2019, Orifarm Group has a target of revenue growth in the range of 3-6 % and an operating income at 2018 level. 

For more information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351

CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121

 

Key figures, Orifarm Group (in MEUR)

 

  2018

2017

2016

2015

Net turnover

833

797

726

759

Gross result

131

120

109

97

Result of main activities excl. non-recurring items

40

34

32

23

Result of financial items

-4

-5

-8

-9

Result before tax

35

29

16

12

 

Facts about Orifarm Group

Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in import, production, re-packaging, distribution, registration and sales of pharmaceuticals. The Group is engaged in parallel importing of pharmaceuticals from EU countries, which are sold in Denmark, Norway, Sweden, Finland, Germany, Holland, Austria and the United Kingdom.

Additionally, the Group is engaged in the sales of generic pharmaceuticals in the Nordics. A generic product contains the same active ingredients as the original product. The active ingredients are, however, no longer patented, and the generic drug can therefore be produced and sold at a lower price than the original.

The Orifarm Group headquarters are in Odense, Denmark. The Group employs approximately 1.200 people.

18.05.2018

Record-breaking result from Orifarm Group

Orifarm Group manages to provide cheaper pharmaceuticals to millions of consumers in Europe while earning money to invest in future activities. Despite fierce competition, Orifarm closes its fiscal year 2017 with an annual result showing 10 percent growth in net turnover and the second best earnings in the history of the company.

Orifarm Group manages to provide cheaper pharmaceuticals to millions of consumers in Europe while earning money to invest in future activities. Despite fierce competition, Orifarm closes its fiscal year 2017 with an annual result showing 10 percent growth in net turnover and the second best earnings in the history of the company.

This week Orifarm Group presents the financial statement of 2017 and the Danish-owned pharmaceutical company continues to do well. The Group's net turnover increased by 10 percent to EUR 797 million in 2017, the result of main activities rose to EUR 34 million and the result before tax increased to EUR 29 million.

 


Lower priced parallel imported products are the main driver

The improved Orifarm Group results are in particular due to the parallel import business handled by Orifarm Parallel Import. The business division showed a positive development and reasonable results throughout mature as well as new markets. Orifarm Parallel Import, which repackages and sells pharmaceuticals within the EU - and constitutes the largest of the two business areas - accounts for a net turnover of EUR 720 million. This is an increase in net turnover of 11 percent when compared to 2016. Results of main activities excl. non-recurring items rose by EUR 4.2 million to EUR 26.2 million.

Generic products, which are the Group's second business area and handled by Orifarm Generics, completed 2017 with a slight decline in net turnover as well as earnings. Net turnover for 2017 ended at EUR 77 million, which represents a decrease of EUR 2 million when compared to 2016. Results of main activities excl. non-recurring items decreased by EUR 2 million to EUR 12.3 million. The 2017 results follow several years of strong growth in Orifarm Generics, and Orifarm Group is now investing significantly to ensure future growth in the business area.

President and CEO Hans Bøgh-Sørensen is very satisfied with the 2017 Group result:

"In 2017, the parallel import business has performed very well. It is an area of fierce competition among many companies. Consequently, it requires a dedicated and focused organization with ambitious employees who understand how to make a good deal on behalf of society, consumers and Orifarm”, he says, continuing: "our mission is to challenge the pharmaceutical market to ensure a ‘better deal’ for all and, of course, I am happy to see when we succeed in doing this."

Especially Germany, Orifarm's largest single market for parallel imported products, has contributed significantly to the excellent result, despite the intense competition and the same applies to Denmark. Orifarm is also successful in gaining ground in the new markets. In particular, the Netherlands and Austria contributed positively to the results in 2017.


Orifarm Group invests further in generic products

After several years of great success and significant growth within generic products, 2017 became a more even year for Orifarm Generics. Orifarm Generics performed well during the first half of 2017 in Denmark and Sweden, but faced fierce price competition in the second half of 2017 in both countries. However, the management of Orifarm Group remains fully confident that the generic business also has an important role to play in the future. Hans Bøgh-Sørensen elaborates:

"We are convinced that also in the future we can make a big difference for consumers within generics - both in Denmark and in other markets as well. Therefore, the Group is investing heavily in Orifarm Generics' future growth, for instance in an extension of the laboratory at the location in Skælskør, Denmark. In Skælskør, employees work hard to develop new products, which we then produce and sell at favorable prices."

The location in Skælskør houses Viminco, which employs approximately 100 employees. Orifarm Group aquired Viminco in 2015 as part of an increased strategic focus on retail medicine and niche products.


Synergies support future growth

Orifarm is an ambitious company that strives to achieve even better results. In order to ensure the right foundation for future growth, Orifarm has just begun restructuring the company. Hans Bøgh-Sørensen says:

We see many changes in Orifarm´s environment these years and our business is developing rapidly. As responsible managers, we must always ensure that the company and the employees are well equipped to meet the challenges of the future. Therefore, we have just decided to break down the silos internally and merge the two business areas to a higher degree than we have had so far. In this way, we expect to benefit from the many synergies that exist across the two business areas, thus creating a solid foundation for further growth in the Group."

Orifarm Group expects activity and results for 2018 to be at same level as 2017.
 

For more information, please contact:

Deputy CEO, Orifarm Group A/S, Erik Sandberg at +45 22 65 01 21.
Corporate Communications at +45 22 65 01 22.


2017 financial highlights

Key figures, Orifarm Group (in MEUR)

 

2017

2016

2015

2014

Net turnover

797

726

759

755

Gross result

120

109

97

91

Result of main activities excl. non-recurring items

34

32

23

16

Result of financial items

-5

-8

-9

-8

Result before tax

29

16

12

9

 

Facts about Orifarm Group

Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and the largest supplier of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in import, production, re-packaging, distribution, registration and sales of pharmaceuticals. The Group is engaged in parallel importing of pharmaceuticals from EU countries, which are sold in Denmark, Norway, Sweden, Finland, Germany, Holland, Austria and the United Kingdom. Additionally, the Group is engaged in the sales of generic pharmaceuticals in the Nordics. A generic product contains the same active ingredients as the original product. The active ingredients are, however, no longer patented, and the generic drug can therefore be produced and sold at a lower price than the original.

The Orifarm Group headquarters are in Odense, Denmark. The Group employs approximately 1.100 employees.

31.05.2016

Progress continues at Orifarm

Orifarm Group continues its progress of recent years. The annual result shows growth in both top and bottom line, and this trend is partly due to successful acquisitions and significant growth in the sales of generic pharmaceuticals.

Orifarm Group continues its progress of recent years. The annual result shows growth in both top and bottom line, and this trend is partly due to successful acquisitions and significant growth in the sales of generic pharmaceuticals.

Denmark’s largest supplier of pharmaceuticals, Orifarm, continues the positive trend that has characterized the last years of the group.

Orifarm ended the financial year 2015 with a profit before tax of 11.5m EUR. An increase of 32% compared to the results from 2014 of 8.7m EUR.  At the same time, the Group achieved a slight increase in revenue to 759m EUR.

Particularly the area of generic pharmaceuticals, Orifarm Generics, presents significantly improved earnings in 2015 with an increase of 2.6m EUR (+ 51%) compared to 2014.

The increase in own-produced pharmaceuticals is partly due to a successful acquisition of Growth House Holding A/S, which develops, produces and sells pharmaceuticals. Additionally, the company sees continued growth in the Nordic region with increased sales of both prescription and non-prescription drugs.

“It is extremely satisfying that we continue the significant progress during 2015. In particular, the acquisition of Growth House Holding A/S has been strategically important compared to the growth journey that Orifarm Generics is currently on. Moreover, our development, production and sale of own-produced products has been strengthened”, says Ulrik Ernst Rasmussen, Managing Director of Orifarm Generics.

In the area for parallel importation of pharmaceutical drugs from EU/EEA countries, Orifarm Parallel Import also continues Orifarm’s overall positive trends, and here the group’s largest revenue still remains.

The year 2015’s profit, however, was affected negatively by the development in the Swedish currency as well as increased competition in the German market. But due to a reduction of the cost level, Orifarm Parallel Import still managed to create growth in the EBITDA of 4.2m EUR compared to 2014. At the same time Orifarm has entered into the UK market, the second largest market for parallel imported pharmaceuticals in Europe.

“I am very pleased that Orifarm continues the positive trend and presents a good result for 2015.

This year has been subject to challenges on the markets in i.e. Sweden and Germany, but at the same time we have succeeded in entering the large UK market. This development is to a large extent the result of the employees' great efforts”, says Erik Sandberg, Managing Director of Orifarm Parallel Import, adding that strategic optimization, management of inventory and cost savings also contributed positively to the financial statement.

Orifarm Group expects improved financial statements in 2016 compared to 2015 and growth in the financial statements for both Orifarm Generics and Orifarm Parallel Import.

Orifarm Group is headquartered in Odense, Denmark and employs around 1,100 employees.

For further information please contact:
CEO Orifarm Group A/S Hans Bøgh-Sørensen, phone +45 29 74 27 10

CEO Orifarm PI A/S Erik Sandberg, phone +45 22 65 01 21

CEO Orifarm Generics A/S Ulrik Ernst Rasmussen, phone +45 22 65 01 91

Key figures (MEUR)

 

2015

2014

2013

2012

Revenue

759

755

727

667

Gross result

97

91

96

93

Result of main activities excl. re-structuring

23

16

16

11

Result of financial items

-9

-8

-8

-12

Result before tax

12

9

8

-1

 

Facts about Orifarm

Orifarm Group is the largest parallel importer of pharmaceuticals and the largest supplier of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in the import, production, re-packaging, distribution, registration and sale of pharmaceuticals in Scandinavia, Germany, Holland, Czech Republic and United Kingdom. The Group’s main business is parallel importing of pharmaceuticals from EU/EEA countires, which are sold in Denmark, Norway, Sweden, Finland, Holland, Germany and United Kingdom. Additionally, the group is engaged in the sales of generic pharmaceuticals in Scandinavia. A generic drug contains the same active ingredients as the original drug. The active ingredients are, however, no longer patented, and therefore the generic drug can be produced and sold at a lower price than the original.

06.07.2015

Orifarm Generics on hankkinut Alternovan, Vimincon ja Pilum Pharman

Orifarm Groupin tytäryhtiö Orifarm Generics on hankkinut Growth House Holdingin, johon kuuluvat yritykset Alternova, Viminco ja Pilum Pharma. Growth House Holding kehittää, valmistaa ja myy rinnakkaislääkevalmisteita Pohjoismaissa.

Orifarm Groupin tytäryhtiö Orifarm Generics on hankkinut Growth House Holdingin, johon kuuluvat yritykset Alternova, Viminco ja Pilum Pharma. Growth House Holding kehittää, valmistaa ja myy rinnakkaislääkevalmisteita Pohjoismaissa. Noin sata työntekijää työllistävien Growth Housen yritysten hankinnan myötä Orifarm Geenrics on ottanut tärkeän strategisen askeleen kohti kasvun kiihdyttämistä.

Growth Housen yritysten hankinta kertoo Orifarm Groupin halusta kasvattaa osuuttaan Pohjoismaiden rinnakkaislääkemarkkinoilla. Kyse on kahden menestyneen lääkeyhtiön fuusiosta. Molemmat osapuolet odottavat yhteistyötä innolla.

Growth Houseen kuuluvalla Vimincolla on oma tuotantonsa ja laboratorionsa, joita Orifarm Genericsillä ei ole tätä ennen ollut. Niinpä hankinta kasvattaakin yrityksen kapasiteettia.

"Tämä on hyvä kauppa, joka täydentää ja vahvistaa liiketoimintaamme entisestään, sillä nyt voimme keskittyä lääkkeiden kehitystyöhön oman talon sisällä. Lanseerasimme vuoden 2014 jälkipuoliskolla ensimmäisen itse kehittämämme tuotteet, josta tuli välittömästi menestys. Seuraava tuote lanseerattiin tämän vuoden toukokuussa. Yrityskauppa tuo aloittamallemme kehitystyölle mukavan piristysruiskeen. Olemme varmoja, että liiketoimintamme kasvaa entisestään seuraavien vuosien aikana," kertoo Orifarm Genericsin toimitusjohtaja Ulrik Rasmussen.

Orifarm Group julkaisi hiljattain tilinpäätöksensä, joka kertoi vakaasta kasvusta erityisesti rinnakkaisvalmisteiden myynnin osalta. Näin ollen yrityskauppa on tärkeä askel kohti konsernin rinnakkaisvalmistetoimintaa koskevien tavoitteiden saavuttamista.

"Tuotevalikoimamme täydentävät toisiaan erinomaisesti. Growth Housella on mielenkiintoinen tuotevalikoima, johon me nyt pääsemme käsiksi. Luotamme siihen, että uusi yksikkö vakiinnuttaa asemamme Pohjoismaiden rinnakkaisvalmisteiden varteenotettavana toimijana," Ulrik Rasmussen jatkaa.

Growth Housessa on tehty viime vuosina hyvin jännittäviä muutoksia. Yritys on etsinyt uusia sijoittajia voidakseen toteuttaa kasvua koskevat haaveensa.

"Meillä on jo ennestään läheinen ja arvokas yhteistyösuhde Orifarmiin, sillä olemme valmistaneet yhtä Orifarmin tuotteista. Niinpä pidämme Orifarmille myymistä oikeana päätöksenä. Olemme varmoja, että nykyinen menestyksemme jatkuu uusien omistajien käsissä," sanoo Vimincon toimitusjohtaja Rolf Eckersberg.
Orifarm Groupin pääkonttori sijaitsee Odensessa. Orifarm Group työllistää noin 1 000 ihmistä.

Lisätietoja:

CEO Orifarm Generics A/S Ulrik Ernst Rasmussen: +45 22 65 01 91

Tietoa Orifarmista

Orifarm Group on Euroopan suurin lääkkeiden rinnakkaismaahantuoja ja Tanskan suurin lääkkeiden maahantuoja. Konserniin kuuluu lukuisia yrityksiä, jotka ovat erikoistuneet lääkevalmisteiden maahantuontiin, valmistukseen, uudelleenpakkaamiseen, jakeluun, rekisteröintiin ja myyntiin niin Pohjoismaissa, Saksassa, Hollannissa, Tšekissä ja Sveitsissä. Konsernin pääasiallisia toimintoja ovat lääkevalmisteiden rinnakkaistuonti EU/EEA-maista; rinnakkaistuotuja tuotteita myydään Tanskassa, Norjassa, Ruotsissa, Suomessa, Hollannissa ja Saksassa. Lisäksi yritys on erikoistunut rinnakkaislääkevalmisteiden myyntiin Pohjoismaissa. Rinnakkaisvalmisteet sisältävät samat vaikuttavat aineet kuin alkuperäistuotekin. Vaikuttava aine ei kuitenkaan enää ole patenttisuojan alainen, joten sitä saa tuottaa ja myydä halvemmalla kuin samanlaista alkuperäistuotetta.

Tietoa Growth Housesta

Growth House koostuu Alternovasta, Pilum Pharmasta ja Vimencosta. Growth House on lääkeyhtiö, joka kehittää, valmistaa ja myy omia rinnakkaislääkevalmisteitaan Pohjoismaissa. Vimenco sijaitsee Skælskørissa, ja sillä on omat kehitys-, laboratorio- ja tuotantotilansa. Yritys työllistää 80 ihmistä. Alternova ja Pilum Pharma edustavat yrityksen markkinaosastoa. Niiden toimistotilat sijaitsevat Nyborgissa, ja ne työllistävät yhteensä 20 ihmistä.

27.05.2015

Vuosikertomus 2014: Orifarm kehitys jatkuu

Tanskan suurimman lääketoimittajan Orifarm Groupin positiivinen kehitys jatkuu. Vuoden 2014 vuosiluvut kertovat tulojen ja liikevoiton kasvusta. Tämä on pitkälti rinnakkaisvalmistetoiminnan lisääntymisen ansiota.

Tanskan suurimman lääketoimittajan Orifarm Groupin positiivinen kehitys jatkuu. Vuoden 2014 vuosiluvut kertovat tulojen ja liikevoiton kasvusta. Tämä on pitkälti rinnakkaisvalmistetoiminnan lisääntymisen ansiota.

Orifarm Group on Euroopan suurin lääkavalmisteiden rinnakkaistuontiyritys ja Tanskan suurin lääkevalmisteiden toimittaja. Yritys on parantanut tulostaan viime vuosien aikana, ja sama positiivinen trendi jatkuu myös vuoden 2014 tilinpäätöksessä.

Yrityksen tulot ovat kasvaneet 4 %. Liikevoitto ennen veroja on kasvanut 8 miljoonalla Tanskan kruunulla. Vuosina 2012/2013 käynnistetyt strategiset aloitteet ja toimet näkyvät nyt myös yrityksen tuloksessa.

Kaiken kaikkiaan yrityksen nettomyynti kasvoi vuoden 2013 EUR 724 miljoonasta EUR 750 miljoonaan vuonna 2014.
Liikevoitto kasvoi EUR 0,4 miljoonasta EUR 1,63 miljoonaan. Kokonaisvoitto ennen veroja on EUR 8,7 miljoonaa, mikä tarkoittaa EUR 107 miljoonan kasvua vuodesta 2013.


Lisätietoja:
CEO Orifarm Group A/S, Hans Bøgh-Sørensen, + 45 29 74 27 10
CEO Orifarm PI A/S, Erik Sandberg, +45 22 65 01 21
CEO Orifarm Generics A/S, Ulrik Ernst Rasmussen, +45 22 65 01 91

 

Lataa vuosikertomus

01.03.2014

ERP-järjestelmän vaihto 1. maaliskuuta: Pharma Westen on nyt Orifarm

1. maaliskuuta 2014 lähtien Pharma Westen toimii nimellä Orifarm GmbH. Toiminnanohjausjärjestelmät vaihdettiin osana yrityksen uudelleennimeämistä. Nyt kaikki lääkevalmisteet voidaan tilata uuden Orifarm-nimen kautta (lyhenne: ORI). 

1. maaliskuuta 2014 lähtien Pharma Westen toimii nimellä Orifarm GmbH. Toiminnanohjausjärjestelmät vaihdettiin osana yrityksen uudelleennimeämistä. Nyt kaikki lääkevalmisteet voidaan tilata uuden Orifarm-nimen kautta (lyhenne: ORI). 

Yritys on ollut osa tanskalaista Orifarmia vuodesta 2005 lähtien. Orifarm on Euroopan johtava kansainvälinen lääkevalmisteiden rinnakkaistuontiyritys. Läheinen yhteistyö emoyhtiön kanssa mahdollistaa sen, että Saksan Orifarmilla on käytössään kansainvälisesti hyväksi todettuja prosesseja. Toimitusjohtaja Ansgar Eschkötter huomauttaa: "Uudelleennimeäminen edustaa entistä läheisempää yhteistyötä ja kokemusten vaihtoa tanskalaisen emoyhtiömme kanssa. Tämä on meille tärkeä muutos, jotta voisimme parantaa asemaamme Saksassa entisestään ja tarjota asiakkaillemme parasta mahdollista palvelua."

Tällä hetkellä rinnakkaistuontiyrityksen lääkevalikoima koostuu noin 800 eri käyttötarkoituksiin tarkoitetusta tuotteesta. Suurin osa tuotteista on reseptilääkkeitä, mutta mukana on myös reseptivapaita lääkkeitä ja diagnostiikkatuotteita. Yritys on myös yksi niistä harvoista saksalaisista rinnakkaistuontiyrityksistä, jotka myyvät huumaavia lääkevalmisteita. Maahantuojaa koskevat samat tiukat laatu- ja turvallisuusmääräykset kuin alkuperäistuotteiden valmistajia. Potilaiden turvallisuus rinnakkaistuontiyrityksessä etusijalla.

Lisätietoja lääkevalmisteiden maahantuonnista löytyy täältä.

Lehdistömateriaalit

Kuvien käyttäminen on ilmaista, kunhan kuvien lähteeksi muistetaan merkitä "Orifarm A/S". Kuvat Orifarmin johtoryhmästä ja perustajaparista saa pyydettäessä. Otat vain meihin yhteyttä osoitteessa cerff@bevsnez.pbz